Clinical trial • Phase III • Neurology
64Cu-DOTA-AE105 for Glioblastoma
Phase III trial of 64Cu-DOTA-AE105 for Glioblastoma. 6 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Glioblastoma
- Trial Stage
- Phase III
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 17-06-2025
- First CTIS Authorization Date
- 22-08-2025
Trial design
Phase III trial across 1 site in Denmark.
- Target Sample Size
- 6
Recruitment
- Planned Sample Size
- 6
- Recruitment Window Months
- 9
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 6
Denmark
- Earliest CTIS Part Ii Submission Date
- 07-08-2025
- Latest Decision Or Authorization Date
- 24-03-2026
- Processing Time Days
- 229
- Number Of Sites
- 1
- Number Of Participants
- 6
Sites
- Site Name
- Rigshospitalet
- Department Name
- Department of Brain and Nerve Surgery
- Principal Investigator Name
- Jane Skjøth-Rasmussen
- Principal Investigator Email
- jane.skjoeth-rasmussen@regionh.dk
- Contact Person Name
- Jane Skjøth-Rasmussen
- Contact Person Email
- jane.skjoeth-rasmussen@regionh.dk
- Number Of Participants
- 6
Sponsor
Primary sponsor
- Full Name
- Curasight A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- 64Cu-DOTA-AE105-201
- Active Substance
- 64Cu-DOTA-AE105
- Modality
- Radiopharmaceutical
Related trials
Other published trials that may interest you.